Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696313 | 0.84 | MAPT (0.63) | MAPTSMN1; SMN2KMT2ANPC1LMNA | |
| SCHEMBL6692679 | 0.82 | CA12 (0.58) | EPHX2MAPTKMT2APOLBALDH1A1 | |
| SCHEMBL3146895 | 0.81 | FPR2 (0.66) | MAPTSMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL6697390 | 0.80 | CA12 (0.56) | ALDH1A1FAAH | |
| SCHEMBL6689381 | 0.78 | FAAH (0.56) | ALDH1A1FAAH | |
| SCHEMBL6380819 | 0.78 | EPHX1 (0.67) | EPHX2SMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL7308225 | 0.77 | KMT2A (0.67) | EPHX2MAPTSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL6688599 | 0.77 | NOX1 (0.61) | SMN1; SMN2KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL4950227 | 0.76 | EPHX2 (0.48) | EPHX2MAPTSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL10802920 | 0.76 | CNR1 (0.63) | MAPTSMN1; SMN2KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300010-B1 | PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKERS | NOVARTIS AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-8236808-B2 | Pyrazine derivatives as ENAC blockers | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-20110201625-A1 | Organic Comopunds | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| CN-102112130-A | Pyrazine derivatives as epithelial sodium channel blockers | NOVARTIS AG | 2011-06-29 | — | — | CN | disclosed |
| EP-2300010-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009150137-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201625-A1 | Organic Comopunds | OR10J3, CFTR, CLIC1 | EPHX2 1723/4885MAPT 1914/4885SMN1; SMN2 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.